Denosumab for the prevention of osteoporotic fractures in postmenopausal women

TA204 Osteoporotic fractures - denosumab: review decision - March 2014 information

TA204 Osteoporotic fractures - denosumab: Appendix B - GE decision paper - March 2014 (PDF 309 KB)

TA204 Osteoporotic fractures - denosumab: review proposal - August 2013 information

TA204 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix A - provisional matrix of stakeholders (PDF 102 KB)

TA204 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 1.02 MB)

TA204 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix C - Decision Support Unit Report (PDF 560 KB)

TA204 Osteoporotic fractures - denosumab: review update - August 2012 information

TA204 Osteoporotic fractures - denosumab: press release information

2010/152 NICE recommends new treatment option for women at increased risk of osteoporotic fractures (PDF 87 KB)

Osteoporotic fractures - denosumab: final appraisal determination (FAD) information

Osteoporotic fractures - denosumab: final appraisal determination document (PDF 268 KB)

Consultee and commentator comments on the ACD

Amgen (PDF 147 KB)

Society for Endocrinology (PDF 7.6 KB)

Royal College of Nursing (PDF 54 KB)

Novartis (PDF 314 KB)

Servier Laboratories (PDF 59 KB)

Warner Chilcott UK (PDF 7.7 KB)

National Osteoporosis Society (PDF 55 KB)

Expert comments on the ACD

Professor Jon Tobias (PDF 45 KB)

Professor Roger Francis (PDF 40 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Table of comments and responses (PDF 367 KB)

ERG exploratory analyses following ACD consultation (PDF 227 KB)

Osteoporotic fractures - denosumab: appraisal consultation

Osteoporotic fractures: appraisal consultation document information

Osteoporotic fractures - denosumab: evaluation report

Osteoporotic fractures - denosumab: pre-meeting briefing (PDF 325 KB)

Osteoporotic fractures - denosumab: evidence review group report (PDF 860 KB)

Osteoporotic fractures - denosumab: non-manufacturer submissions

Osteoporotic fractures - denosumab: National Osteoporosis Society (PDF 72 KB)

Osteoporotic fractures - denosumab: Royal College of Pathologists (PDF 107 KB)

Osteoporotic fractures - denosumab: Society and College of Radiographers (PDF 53 KB)

Osteoporotic fractures - denosumab: Manufacturer submission (PDF 3.84 MB)

Osteoporotic fractures - denosumab: manufacturer response to clarification

Osteoporotic fractures - denosumab: manufacturer response to clarification February 2010 (PDF 178 KB)

Osteoporotic fractures - denosumab: manufacturer response to clarification March 2010 (PDF 613 KB)

Osteoporotic fractures - denosumab: manufacturer identification of factual inaccuracies in the ERG report including ERG comments (PDF 188 KB)

Osteoporotic fractures - denosumab: NICE clarification

Osteoporotic fractures - denosumab: NICE clarification letter 11 February 2010 (PDF 78 KB)

Osteoporotic fractures - denosumab: NICE clarification letter 4 March 2010 (PDF 79 KB)

Osteoporotic fractures - denosumab: expert written personal statements

Osteoporotic fractures - denosumab: Francis (PDF 91 KB)

Osteoporotic fractures - denosumab: Tobias (PDF 63 KB)

Osteoporotic fractures - denosumab: White (PDF 137 KB)

Osteoporotic fractures - denosumab: final scope (PDF 37 KB)

Osteoporotic fractures - denosumab: final matrix (PDF 24 KB)

Osteoporotic fractures - denosumab: response to consultee and commentator comments on the draft scope (PDF 80 KB)

Osteoporotic fractures - denosumab: response to consultee and commentator comments on the provisional matrix (PDF 30 KB)